SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : Imclone systems (IMCL) -- Ignore unavailable to you. Want to Upgrade?

To: Sea Otter who wrote (482)3/18/1999 10:55:00 PM
From: 5,17,37,5,101,...  Read Replies (2) | Respond to of 2515
 
Sea Otter,

Yes, I remember reading the details but cant remember where. Here is something that might tide you over until I find it:

infotrieve.com

Jackson



To: Sea Otter who wrote (482)3/20/1999 8:15:00 AM
From: Tim Williams  Read Replies (1) | Respond to of 2515
 
Sea Otter, the abstract for the phase II trail of BEC2 can be found at, asco.org Look under 1997 abstracts and search for
BEC2. In summary, median survival of 15 BEC2 patients 20.5 months vs 17.9 for reference group of traditionally treated patients.


HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News